Trials / Completed
CompletedNCT05886881
Air Optix Extended Wear Contact Lenses
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 505 (actual)
- Sponsor
- Alcon Research · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this Post-Market Clinical Follow-Up (PMCF) study is to assess long term performance and safety of Air Optix Aqua Sphere, Air Optix plus HydraGlyde Sphere, and Air Optix plus HydraGlyde Toric soft contact lenses in a real-world setting when worn as extended (overnight) wear.
Detailed description
This is a non-interventional/observational study designed as a retrospective chart review. Study sites will identify charts within their existing databases in a fair and consistent manner, e.g., reviewing all eligible charts in reverse chronological order by year of baseline visit. Subjects/charts meeting the eligibility criteria will be enrolled in the study. The data collection period is defined as any approximately 1-year to 3-year timeframe since the respective lens brand was prescribed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Lotrafilcon B spherical soft contact lenses | Commercially available silicone hydrogel contact lenses |
| DEVICE | Lotrafilcon B spherical soft contact lenses with comfort additive | Commercially available silicone hydrogel contact lenses |
| DEVICE | Lotrafilcon B toric soft contact lenses with comfort additive | Commercially available silicone hydrogel contact lenses |
| DEVICE | Comfilcon A spherical soft contact lenses | Commercially available silicone hydrogel contact lenses |
| DEVICE | Comfilcon A toric soft contact lenses | Commercially available silicone hydrogel contact lenses |
Timeline
- Start date
- 2023-08-03
- Primary completion
- 2025-04-15
- Completion
- 2025-04-15
- First posted
- 2023-06-02
- Last updated
- 2025-08-14
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT05886881. Inclusion in this directory is not an endorsement.